Generic Name and Formulations:
Miglitol 25mg, 50mg, 100mg; tabs.
Indications for GLYSET:
Adjunct to diet in type 2 diabetes, alone or with a sulfonylurea.
Take with the first bite of each main meal. Initially 25mg three times daily; may start at 25mg once daily (to minimize GI effects) and gradually increase to 25mg three times daily. Increase to 50mg three times daily after 4–8 weeks; usual max 100mg three times daily.
Ketoacidosis. Inflammatory bowel disease. Colonic ulceration. Partial intestinal obstruction or predisposition thereof. Chronic intestinal diseases associated with marked disorders of digestion or absorption. Conditions that may deteriorate from increased intestinal gas formation.
Significant renal dysfunction (serum creatinine >2mg/dL): not recommended. Use glucose, not sucrose, to treat hypoglycemia. Stress. Monitor 1-hour postprandial blood glucose initially and during titration then glycosylated hemoglobin. Pregnancy (Cat.B): consider using insulin instead. Nursing mothers: not recommended.
Antagonized by intestinal adsorbents (eg, charcoal), pancreatin, amylase, other carbohydrate-splitting enzymes. May decrease levels of ranitidine, propranolol. Risk of hypoglycemia with concomitant sulfonylureas or insulin; consider reducing dose of these.
Transient flatulence, diarrhea, abdominal pain; low serum iron.
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Pharmacologically Induced Headache Accompanied by Dilated Cephalic Vessels
- IV Lidocaine May Be Safe, Efficacious for Pediatric Status Migraine
- Gray Matter Changes in Migraine Associated With Clinical Characteristics